What if we’re finally moving beyond managing autoimmune diseases and toward slowing their progression? That’s the promise behind Immunic Therapeutics' recent long-term data on vidofludimus calcium (IMU‑838. Dr Daniel Vitt, CEO of Immunic, discusses these results and insights with DDW’s Megan Thomas. MT: Can you unpack what the sustained neuroprotective effects tell us about Nurr1 […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!